Treatment of Pulmonary Embolism beyond Anticoagulation
Curr Pharm Des. 2024 Apr 24. doi: 10.2174/0113816128308493240418075258. Online ahead of print.NO ABSTRACTPMID:38659268 | DOI:10.2174/0113816128308493240418075258 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 25, 2024 Category: Drugs & Pharmacology Authors: Lampros Lakkas Christos S Katsouras Source Type: research
Complications after peripherally inserted central catheter versus central venous catheter implantation in intensive care unit: propensity score analysis using a nationwide database
CONCLUSIONS: Patients with PICCs had a significantly greater incidence of complications than did those with CVCs. Further research is necessary to explore the factors contributing to these complications.PMID:38661659 | DOI:10.1080/17434440.2024.2346191 (Source: Expert Review of Medical Devices)
Source: Expert Review of Medical Devices - April 25, 2024 Category: Medical Devices Authors: Toshiaki Takahashi Kojiro Morita Kazuaki Uda Hiroki Matsui Hideo Yasunaga Gojiro Nakagami Source Type: research
Long-term incidence, risk factors and complications for venous thromboembolism in patients with systemic lupus erythematosus
CONCLUSIONS: VTE affected 12.8% of patients with SLE at six times the VTE rate in controls with aPL as the strongest, but not the only risk factor in SLE. The risk of PH was increased in both groups following PE, but VTE did not associate with an increased risk of arterial events.PMID:38655753 | DOI:10.1177/09612033241247359 (Source: Lupus)
Source: Lupus - April 24, 2024 Category: Rheumatology Authors: Johannes Cornelis Nossent Helen Isobel Keen David Brian Preen Charles Anoukpar Inderjeeth Source Type: research
Thrombus or tumor? A case report of a rare sarcoma entity: intimal sarcoma of the pulmonary arteries
CONCLUSION: In case of atypical presentation of a pulmonary embolism, a tumor originating from the great vessels should be considered. Molecular pathology techniques support in establishing a reliable diagnosis.PMID:38656400 | DOI:10.1007/s11033-024-09467-9 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - April 24, 2024 Category: Molecular Biology Authors: A D örr A Fl örcken L Bullinger D Capper A Von Deimling D Kaul S M ärdian C Starck D Horst M P Dragomir F M Sch äfer A Jarosch Source Type: research
Thrombus or tumor? A case report of a rare sarcoma entity: intimal sarcoma of the pulmonary arteries
CONCLUSION: In case of atypical presentation of a pulmonary embolism, a tumor originating from the great vessels should be considered. Molecular pathology techniques support in establishing a reliable diagnosis.PMID:38656400 | DOI:10.1007/s11033-024-09467-9 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - April 24, 2024 Category: Molecular Biology Authors: A D örr A Fl örcken L Bullinger D Capper A Von Deimling D Kaul S M ärdian C Starck D Horst M P Dragomir F M Sch äfer A Jarosch Source Type: research
Evidence-Based Update on Transcatheter Therapies for Pulmonary Embolism
AbstractPurpose of ReviewPulmonary embolism (PE) remains a leading cause of cardiovascular morbidity and mortality. Multiple new therapies are in development and under study to improve our contemporary care of patients with PE. We review and compare here these novel therapeutics and technologies.Recent FindingsMultiple novel therapeutic devices have been developed and are under active study. This work has advanced the care of patients with intermediate and high-risk PE.SummaryNovel therapies are improving care of complex PE patients. These have inspired large multicenter international randomized controlled trials that are ...
Source: Current Cardiology Reports - April 24, 2024 Category: Cardiology Source Type: research
Optimization of CT pulmonary angiography for pulmonary embolism using task-based image quality assessment and diagnostic reference levels: A multicentric study
Computed tomography (CT) pulmonary angiography (CTPA) is currently the standard of care to quickly and accurately diagnose pulmonary embolism (PE) [1]. The number of CTPA examinations has considerably increased in the last fifteen years [2,3]. In Switzerland, a recent survey showed that despite the increased number of CT examinations, the effective dose has decreased due to efforts to optimize clinical protocols [2]. (Source: Physica Medica: European Journal of Medical Physics)
Source: Physica Medica: European Journal of Medical Physics - April 24, 2024 Category: General Medicine Authors: Ana ïs Viry, Veronika Vitzthum, Pascal Monnin, Julie Bize, David Rotzinger, Damien Racine Tags: Original paper Source Type: research
Selective binding of cationic fibrinogen-mimicking chitosan nanoparticles to activated platelets and efficient drug release for antithrombotic therapy
Int J Biol Macromol. 2024 Apr 21:131742. doi: 10.1016/j.ijbiomac.2024.131742. Online ahead of print.ABSTRACTThrombosis is the main cause of catastrophic events including ischemic stroke, myocardial infarction and pulmonary embolism. Acetylsalicylic acid (ASA) therapy offers a desirable approach to antithrombosis through a reduction of platelet reactivity. However, major bleeding complications, severe off-target side effects, and resistance or nonresponse to ASA greatly attenuate its clinical outcomes. Herein, we report a cationic fibrinogen-mimicking nanoparticle, denoted as ASA-RGD-CS@TPP, to achieve activated-platelet-ta...
Source: International Journal of Biological Macromolecules - April 23, 2024 Category: Biochemistry Authors: Yu Huang Jiahua Wang Yuanyuan Guo Seun Young Park Hongtian Yang Annabelle Lu Yuehua Li Rongjun Chen Source Type: research
Selective binding of cationic fibrinogen-mimicking chitosan nanoparticles to activated platelets and efficient drug release for antithrombotic therapy
Int J Biol Macromol. 2024 Apr 21:131742. doi: 10.1016/j.ijbiomac.2024.131742. Online ahead of print.ABSTRACTThrombosis is the main cause of catastrophic events including ischemic stroke, myocardial infarction and pulmonary embolism. Acetylsalicylic acid (ASA) therapy offers a desirable approach to antithrombosis through a reduction of platelet reactivity. However, major bleeding complications, severe off-target side effects, and resistance or nonresponse to ASA greatly attenuate its clinical outcomes. Herein, we report a cationic fibrinogen-mimicking nanoparticle, denoted as ASA-RGD-CS@TPP, to achieve activated-platelet-ta...
Source: International Journal of Biological Macromolecules - April 23, 2024 Category: Biochemistry Authors: Yu Huang Jiahua Wang Yuanyuan Guo Seun Young Park Hongtian Yang Annabelle Lu Yuehua Li Rongjun Chen Source Type: research
Categorization of Patients with Pulmonary Embolism by Charlson Comorbidity Index
Pulmonary embolism is a cardiovascular life-threatening acute event afflicted by high morbidity and mortality.1-6 While the annual incidence of pulmonary embolism has increased in the past decades, the case fatality of this emergency event decreased in the same time.3,7-9 Mortality caused by pulmonary embolism is strongly and closely related to the patients ’ hemodynamic status and cardiac involvement, including right ventricular dysfunction and/or myocardial injury, as well as the patients’ comorbidity profile. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - April 23, 2024 Category: General Medicine Authors: Karsten Keller, Volker H. Schmitt, Omar Hahad, Christine Espinola-Klein, Thomas M ünzel, Philipp Lurz, Stavros Konstantinides, Lukas Hobohm Tags: Clinical Research Study Source Type: research
Contemporary Management of Pulmonary Embolism: Review of the Inferior Vena Cava filter and Other Endovascular Devices
Int J Angiol DOI: 10.1055/s-0044-1785231Inferior vena cava (IVC) filters and endovascular devices are used to mitigate the risk of pulmonary embolism in patients presenting with lower extremity venous thromboembolism in whom long-term anticoagulation is not a good option. However, the efficacy and benefit of these devices remain uncertain, and controversies exist. This review focuses on the current use of IVC filters and other endovascular therapies in clinical practice. The indications, risks, and benefits are discussed based on current data. Further research and randomized controlled trials are needed to characterize ...
Source: International Journal of Angiology - April 23, 2024 Category: Cardiology Authors: Lei, KaChon DiCaro, Michael V. Tak, Nadia Turnbull, Scott Abdallah, Ala Cyrus, Tillman Tak, Tahir Tags: Review Article Source Type: research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Department
CONCLUSIONS D-dimer and NT-proBNP, but not troponin T, are useful in differentiating CVDs in patients with COVID-19. ACS with COVID-19 increased in-hospital mortality independently from extent of lung involvement, while coexisting APE or AMyo did not.PMID:38644597 | DOI:10.12659/MSM.942612 (Source: Medical Science Monitor)
Source: Medical Science Monitor - April 22, 2024 Category: Research Authors: Micha ł Machowski Aisha Ou-Pokrzewi ńska Katarzyna Perzanowska-Brzeszkiewicz Magdalena Ga łecka-Nowak Szymon Pacho Mateusz Jermakow Agnieszka W ójcik Milena Zoruk Andrzej Pruszczyk Karol Deutsch Marek Roik Andrzej Łabyk Piotr Palczewski Piotr Pruszcz Source Type: research
Modern imaging of acute pulmonary embolism
The first-choice imaging test for visualization of thromboemboli in the pulmonary vasculature in patients with suspected acute pulmonary embolism (PE) is multidetector computed tomography pulmonary angiography (CTPA) – a readily available and widely used imaging technique. Through technological advancements over the past years, alternative imaging techniques for the diagnosis of PE have become available, whilst others are still under investigation. In particular, the evolution of artificial intelligence (AI) i s expected to enable further innovation in diagnostic management of PE. (Source: Thrombosis Research)
Source: Thrombosis Research - April 22, 2024 Category: Hematology Authors: C.M.M. de Jong, L.J.M. Kroft, T.E. van Mens, M.V. Huisman, J.L. St öger, F.A. Klok Tags: Full Length Article Source Type: research
C-reactive Protein and Risk of Right Ventricular Dysfunction and Mortality in Patients With Acute Symptomatic Pulmonary Embolism
CONCLUSIONS: As an indicator of RV dysfunction, CRP may improve risk stratification algorithms for hemodynamically stable patients with acute symptomatic PE.PMID:38644151 | DOI:10.1016/j.arbres.2024.03.024 (Source: Archivos de Bronconeumologia)
Source: Archivos de Bronconeumologia - April 21, 2024 Category: Respiratory Medicine Authors: Marta Najarro Carmen Rodr íguez Raquel Morillo Luis Jara-Palomares David R Vinson Alfonso Muriel Melchor Álvarez-Mon Roger D Yusen Behnood Bikdeli David Jimenez Source Type: research
C-reactive Protein and Risk of Right Ventricular Dysfunction and Mortality in Patients With Acute Symptomatic Pulmonary Embolism
CONCLUSIONS: As an indicator of RV dysfunction, CRP may improve risk stratification algorithms for hemodynamically stable patients with acute symptomatic PE.PMID:38644151 | DOI:10.1016/j.arbres.2024.03.024 (Source: Archivos de Bronconeumologia)
Source: Archivos de Bronconeumologia - April 21, 2024 Category: Respiratory Medicine Authors: Marta Najarro Carmen Rodr íguez Raquel Morillo Luis Jara-Palomares David R Vinson Alfonso Muriel Melchor Álvarez-Mon Roger D Yusen Behnood Bikdeli David Jimenez Source Type: research
